On November 9, 2026, argenx SE announced a significant move in the biotechnology sector by entering into a definitive agreement to acquire Unnatural Products, Inc. (UNP) for up to $1.15 billion. This acquisition is expected to expand argenx's immunology capabilities and enhance its product offerings aimed at treating serious immune-mediated diseases.
The deal includes an upfront payment of $550 million, with additional payments contingent on the achievement of specific development and regulatory milestones. The acquisition is a strategic step for argenx, which already held a minority stake in UNP, as it seeks to broaden its reach in the biological products market.
Background
argenx SE, a prominent player in the biotechnology field, specializes in developing innovative therapies for patients with serious immune-mediated diseases. The company is listed on both Euronext and Nasdaq under the ticker symbol ARGX. With a focus on biological products, argenx aims to leverage novel biology to create effective treatments. The company has been actively filing reports with the SEC, including a recent filing on November 9, 2026, detailing this acquisition.
What the Filing Says
The SEC filing states, "On November 9, 2026, argenx SE issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference herein." The press release outlines the key aspects of the acquisition, highlighting the strategic importance of UNP's peptide discovery engine to argenx's existing capabilities.
Impact
This acquisition is poised to impact various stakeholders, including patients, healthcare providers, and competitors in the biological products sector. By integrating UNP's expertise in peptide discovery with its own antibody engineering, argenx plans to develop oral and long-acting medicines, potentially reaching more patients with innovative therapies. The move may also intensify competition within the industry as other companies respond to argenx's strengthened position.
What's Next
The boards of directors of both companies have approved the transaction, which is expected to close by the end of the year, pending customary closing conditions. This acquisition marks a significant milestone for argenx as it continues to invest in its growth and innovation strategies.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





